Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
Tense negotiations between the UK government and the pharmaceutical industry over a new drug pricing framework have concluded with a far-reaching agreement. 20 November 2023
Pharmaceutical
Bayer shares plunged to their lowest in a decade after the German pharma major said it would discontinue a late-stage trial for a blood-thinning drug for heart disease that had failed to demonstrate efficacy. 20 November 2023
Pharmaceutical
The UK’s largest drugmaker, AstraZeneca, has announced the launch of a new AI-focused digital health solutions company, to be called Evinova. 20 November 2023
Pharmaceutical
Leerink Partners analysts have published a Leerink Healthcare Team report on GLP1s+ (ie, including new drug mechanisms) to potentially transform the healthcare industry. 20 November 2023
Pharmaceutical
Buoyed by its recent approval in obesity, Eli Lilly has announced a massive new investment in manufacturing capacity in Europe. 17 November 2023
Pharmaceutical
A feature analyzing how - and why - cardiology is of renewed interest to pharma. 17 November 2023
Pharmaceutical
The National Institute for Health and Care Excellence (NICE) has issued its Final Draft Guidance (FDG) recommending Jardiance (empagliflozin) as an option for the treatment of eligible adults with chronic kidney disease (CKD) in England and Wales. 17 November 2023
Pharmaceutical
A worrying drop in the number of clinical trials launched in the UK could be coming to an end, early figures suggest. 17 November 2023
Pharmaceutical
GLP-1 agonists are transforming the way cardiometabolic disorders are treated, with new approvals in obesity opening the door to significant new treatment opportunities. 17 November 2023
Pharmaceutical
The UK’s Competition and Markets Authority (CMA) has clarified the circumstances under which it will not prioritize enforcement action against pharmaceutical companies when they implement a specific ‘negotiation framework’ to make more combination therapies available on the National Health Service (NHS). 17 November 2023
Pharmaceutical
Vision-focused biopharma LENZ Therapeutics and Graphite Bio have entered into a definitive merger agreement to combine the companies in an all-stock transaction. 16 November 2023
Pharmaceutical
Japanese pharma major Astellas Pharma has entered into a merger agreement to acquire Propella Therapeutics. 16 November 2023
Pharmaceutical
Shares of US biopharma CorMedix rose as much as 18% ad closed up 6.4% at $3.33 yesterday, after it revealed that the US Food and Drug Administration (FDA) has approved its DefenCath (taurolidine and heparin). 16 November 2023
Pharmaceutical
Some 500 jobs are to go at US pharma giant Pfizer’s UK site in Sandwich, Kent. 15 November 2023
Pharmaceutical
Markets have reacted warmly to a radical plan from Theseus Pharmaceuticals to cut costs and potentially put itself up for a sale or merger. 15 November 2023
Pharmaceutical
German life sciences and pharma company Merck KGaA, which operates its Healthcare business as EMD Serono in the USA and Canada, yesterday announced that it plans to move its US Healthcare headquarters, currently located in Rockland, Massachusetts, to Boston’s Seaport district. 15 November 2023
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today extended the license of the cystic fibrosis medicines Kaftrio (ivacaftor, tezacaftor and elexacaftor) and Kalydeco (ivacaftor) for children aged two to five years old. 15 November 2023
Pharmaceutical
The USA's Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness and value of sotatercept for pulmonary arterial hypertension (PAH). 14 November 2023
Pharmaceutical
Ipsen and fellow French drugmaker Genfit presented full results from the pivotal Phase III ELATIVE trial in a late-breaking oral session) at the American Association for the Study of Liver Diseases (AASLD) late yesterday. 14 November 2023
Pharmaceutical
Swiss drugmaker Basilea Pharmaceutica has entered into an asset purchase agreement with Amplyx Pharmaceuticals to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. 14 November 2023
All news
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Pharmaceutical
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space.
How has the company achieved this — on the R&D and patient access side — and what is the company doing to help the remaining patients? Vertex’s Andrew Wilfin, Senior Country Medical Director, UK and Ireland, took part in a Q&A with The Pharma Letter to reveal all. 7 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial intelligence (AI) intended to support a regulatory decision about a drug or biological product’s safety, effectiveness or quality. 7 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze